Shots:
- CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, reported EMA’s CHMP has granted a positive opinion to Dazublys (150 mg powder for concentrate for solution for infusion), its trastuzumab biosimilar, to treat HER2-positive metastatic and early breast cancers. Pending expected EC approval in July, it will be available across the EU member states
- The opinion was based on its demonstrated similarity to Herceptin in PK, PD, efficacy, safety, and immunogenicity
- Trastuzumab targets and inhibits the HER2 protein, which is overexpressed in certain cancers like breast and gastric cancer
Ref: CuraTeQ | Image: CuraTeQ
Related News:- Celltrion Reports the US FDA approval for Stoboclo & Osenvelt (Biosimilars, Prolia & Xgeva)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
